Tuesday, August 23, 2005

AMLN Update

We've been following AMLN all day.

AMLN's CEO just appeared on CNBC and spoke about the heavy strength the company's shares are experiencing today.

Do you sell into the strength or hold on?

Hold, we say.

AMLN is 2 for 2 this year.

The pop today, CNBC says, is a result of hedge funds getting short squeezed.

As to why hedge funds would short AMLN (AMLN stock fell during the last 6 months) I have no idea.

This is a boutique biotech who has partnered up with several larger players, including Eli Lilly (LLY).

We're issuing a Hold recommendation.

About Us | In the News | Management | Contact Us | Archive | Premium Membership | Terms of Use | Privacy Policy | Careers | FAQ

All quotes are 15 minutes delayed. Copyright © 2006 by Catablast! Media Group LLC, part of the SeekingAlpha network. Web Design by Synexio Systems. All Rights Reserved.